Ribonova is focused on addressing the challenges posed by rare diseases, particularly mitochondrial diseases, which impact a significant number of individuals in the United States. The company is dedicated to discovering and developing innovative medicines aimed at treating these serious conditions. Their lead product candidate, R007, is a small molecule that is ready for Phase 2 clinical trials, specifically targeting inherited mitochondrial diseases. This highlights Ribonova's commitment to advancing therapeutic options for patients suffering from these debilitating disorders.

The company's approach to drug discovery is centered around tRNA technology, which plays a crucial role in the development of their therapeutic candidates. By leveraging this technology, Ribonova aims to create novel treatments that can effectively address the underlying genetic and biochemical challenges associated with mitochondrial diseases. This strategic focus on tRNA drug discovery positions Ribonova as a key player in the field of rare disease therapeutics, with the potential to make a significant impact on patient outcomes.

United States

RiboNova is a privately-held biopharmaceutical company based in the Lankenau Institute for Medical Research near Philadelphia, Pennsylvania. Their product pipeline includes a Phase-2 ready small molecule drug for the treatment of all forms of genetically-confirmed mitochondrial disease and a proprietary drug discovery platform that targets transfer RNA with novel precision medicines for the treatment of mitochondrial and other diseases.

Ribonova

Company Details